Several structural subclasses of ligands bind to the benzodiazepine (BZD) binding site of the GABA A receptor. Previous studies from this laboratory have suggested that imidazobenzodiazepines (i-BZDs, e.g., Ro 15-1788) require domains in the BZD binding site for high-affinity binding that are distinct from the requirements of classic BZDs (e.g., flunitrazepam). Here, we used systematic mutagenesis and the substituted cysteine accessibility method to map the recognition domain of i-BZDs near two residues implicated in BZD binding, ␥ 2 A79 and ␥ 2 T81. Both classic BZDs and i-BZDs protect cysteines substituted at ␥ 2 A79 and ␥ 2 T81 from covalent modification, suggesting that these ligands may occupy common volumetric spaces during binding. However, the binding of i-BZDs is more sensitive to mutations at ␥ 2 A79 than classic BZDs or BZDs that lack a 3Ј-imidazo substituent (e.g., midazolam). The effect that ␥ 2 A79 mutagenesis has on the binding affinities of a series of structurally rigid i-BZDs is related to the volume of the 3Ј-imidazo substituents. Furthermore, larger amino acid side chains introduced at ␥ 2 A79 cause correspondingly larger decreases in the binding affinities of i-BZDs with bulky 3Ј substituents. These data are consistent with a model in which ␥ 2 A79 lines a subsite within the BZD binding pocket that accommodates the 3Ј substituent of i-BZDs. In agreement with our experimental data, computer-assisted docking of Ro 15-4513 into a molecular model of the BZD binding site positions the 3Ј-imidazo substituent of Ro 15-4513 near ␥ 2 A79.
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Benzodiazepines (BZDs) are therapeutic agents commonly used in the treatment of anxiety, sleeplessness, and epilepsy ( Doble and Martin, 1996) . BZDs exert their anxiolytic, hypnotic, and anticonvulsant effects by interacting with a unique modulatory site on the GABA A receptor, the main effector of neuronal inhibition within the central nervous system (Hevers and Lü ddens, 1998) . The BZD binding site is on the extracellular surface of the GABA A receptor at an interface formed by the ␣ and ␥ subunits (Smith and Olsen, 1995; Sigel and Buhr, 1997) . Several studies have identified residues on both the ␣ subunit Amin et al., 1997; Buhr et al., 1997b; Schaerer et al., 1998; Renard et al., 1999; Davies et al., 2001 ) and the ␥ subunit ( Buhr and Sigel, 1997; Buhr et al., 1997a; Wingrove et al., 1997; Kucken et al., 2000) that mediate high-affinity BZD binding; however, the specific interactions between individual amino acids and BZD ligands and the orientation of BZDs within the recognition site remain unclear (for review, see He et al., 2001 ).
The structures of BZD binding site ligands are quite diverse. Classic BZDs, such as flunitrazepam and flurazepam, possess a common 1,4-benzodiazepine nucleus with a 5-phenyl substituent ( Fig. 1 ; Sternbach, 1979) . A different class of BZD ligands possesses both a 5-phenyl substituent and an imidazo ring substituted at positions 1 and 2 of the diazepine nucleus (e.g., midazolam; Fig. 1 ). In contrast, BZDs such as Ro 15-4513 and Ro 15-1788 possess the imidazo ring but lack the 5-phenyl substituent (Fig. 1) . Our research has sought to identify specific domains of the ␥ 2 subunit that are important for binding different structural classes of BZDs and to establish how each class of ligand is oriented within the BZD binding site.
Imidazobenzodiazepines (i-BZDs), such as Ro 15-4513 and Ro 15-1788, seem to possess structural requirements for binding that are distinct from classic BZDs. Previously, we demonstrated that mutation of ␥ 2 A79 had a larger effect on the binding affinities of Ro 15-4513 and Ro 15-1788 than on the classic BZD ligand flunitrazepam (Kucken et al., 2000) . Additionally, Ro15-1788 as well as the classic BZD flurazepam impeded the covalent modification of a cysteine substituted at ␥ 2 A79, whereas modification of ␥ 2 T81C was significantly impeded by Ro15-1788 but not by flurazepam (Teissére and Czajkowski, 2001) . Based on these data, we hypothesized that ␥ 2 A79 and ␥ 2 T81 line part of an i-BZD subsite of the BZD binding site.
In this article, we extend these studies and further test our hypothesis. The binding affinities of seven different BZD ligands were measured after systematic mutation of ␥ 2 A79. In addition, we examined the ability of several BZD ligands with different structures and functional efficacies to slow the rate of covalent modification of ␥ 2 A79C and ␥ 2 T81C. Our studies indicate that ␥ 2 A79 and ␥ 2 T81 contribute to a subsite of the BZD binding pocket that accommodates the 3Ј substituent of the i-BZD imidazo ring (see Fig. 1 ). Using the recently crystallized molluscan acetylcholine binding protein (AChBP) (Brejc et al., 2001 ) as a structural template, we modeled the BZD binding site of the GABA A receptor and describe in part the three-dimensional relationship between i-BZD ligands and the ␥ 2 subunit of the GABA A receptor.
Materials and Methods
Mutagenesis. Rat cDNAs encoding ␣ 1 , ␤ 2 , and ␥ 2S subunits were used for all molecular cloning, radioligand binding, and functional studies. Site-directed mutagenesis of ␥ 2 A79 and ␥ 2 T81 was carried out using recombinant oligonucleotides and the polymerase chain reaction. For radioligand binding, amino acid mutations were made using a myc 9E10 epitope-tagged ␥ 2 subunit as the template. The presence of the epitope had no detectable effect on ligand recognition or on expression of the ␥ 2 subunit (Kucken et al., 2000) . Wild-type and mutant subunits were subcloned into pCEP4 (Boileau et al., 1998) for transient expression in human embryonic kidney (HEK) 293 cells (American Type Culture Collection, Manassas, VA) or into pGH19 (Liman et al., 1992; Robertson et al., 1996) for expression in Xenopus laevis oocytes. All ␥ 2 mutants were verified by restriction enzyme analysis and double-strand DNA sequencing.
Transient Transfection and Radioligand Binding. HEK 293 cells were transiently transfected with ␣ 1 , ␤ 2 , and ␥ 2myc or ␥ 2myc mutant subunits using a standard CaHPO 4 precipitation method (Kucken et al., 2000) . Cells were harvested 48 h after transfection, and membrane homogenates were prepared as described previously (Kucken et al., 2000) . Membrane homogenates (100 g) were incubated at room temperature with [ 3 H]flunitrazepam at sub-K D concentrations for wild-type or mutant receptors and 8 to 11 concentrations of unlabeled ligand in a final volume of 250 l. Data were fit using the equation: Y ϭ B max /[1 ϩ (X/IC 50 )], where Y is the specifically bound disintegrations per minute, B max is the maximal binding, X is the concentration of unlabeled ligand, and IC 50 is the concentration of unlabeled ligand that reduces the maximal specific binding by 50% (GraphPad Software, San Diego, CA). K I values were calculated using the equation: (Cheng and Prusoff, 1973; Chou, 1974) , where K D refers to the equilibrium dissociation constant of the radioligand. The use of this equation assumes that ligand binding follows the law of mass action, is competitive, and that the data reflect one-site binding with no cooperativity. K I values were obtained from at least three independent experiments, each with triplicate determinations. Expression in Oocytes and Electrophysiology. Capped cRNAs encoding the ␣ 1 , ␤ 2 , ␥ 2 , ␥ 2 A79C, or ␥ 2 T81C subunits in pGH19 were transcribed in vitro using the mMessage mMachine T7 kit (Ambion, Austin, TX). Oocytes were harvested from X. laevis and injected within 24 h with 27 nl of cRNA (10-200 pg/nl/subunit) in the ratio 1:1:10 (␣/␤/␥; Boileau et al., 2002) . Expressed receptors were functionally assayed using two-electrode voltage clamp (V hold ϭ Ϫ80 mV, room temp) as described previously (Teissére and Czajkowski, 2001) . Working concentrations of GABA and BZD ligands were made up in ND96 oocyte perfusion solution (96 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , and 5 mM HEPES, pH 7.2). In all electrophysiological experiments, both GABA-activated current (I GABA ) and flurazepam-mediated potentiation of GABA-activated current (I GABA ϩ flurazepam ) were measured. Flurazepam-mediated potentiation of I GABA was defined as [(I GABA ϩ flurazepam /I GABA ) Ϫ 1] ϫ 100. Rates of sulfhydryl-specific covalent modification of ␣ 1 ␤ 2 ␥ 2 A79C or ␣ 1 ␤ 2 ␥ 2 T81C receptors by methanethiosulfonate (MTS) reagents were determined using the following protocol: 1) flurazepam potentiation of I GABA was measured by applying 1 M GABA and then applying 1 M GABA ϩ 1 M flurazepam (corresponding to ϳEC 50 concentration of GABA and ϳEC 80 concentration of flurazepam); 2) the oocyte was washed for 3 min in ND96 buffer; and 3) flurazepam potentiation of I GABA was measured again. This protocol was repeated until flurazepam potentiation of I GABA changed by less than 5%. After potentiation stabilized, the rate of MTS reaction was measured by applying a subsaturating 5 s application of an MTS reagent 30 s after determination of I GABA 
290
(MTSEA-Biotin-CAP; Biotium) as described previously (Teissére and Czajkowski, 2001) .
The decrease in flurazepam potentiation of I GABA was plotted versus cumulative time of MTS exposure and fit to the single-exponential decay equation Y ϭ Ae Ϫkt , where A is the initial potentiation, k is the pseudo-first-order rate constant of the reaction, and t is the time in seconds (GraphPad). The derived pseudo-first-order rate constant was converted into a second-order rate constant (k 2 , M Ϫ1 s
Ϫ1
) by dividing by the concentration of MTS reagent used to correct for the concentration dependence of this effect (Pascual and Karlin, 1998) . To verify the accuracy of the protocol, some of the rate determinations were conducted at two different concentrations of MTS-reagent.
The ability of different BZDs to slow the rate of MTS modification of ␥ 2 A79C and ␥ 2 T81C was assayed by coapplying a BZD with the MTS-reagent during the rate determinations. The following BZDs were tested (all applied at ϳEC 95 concentrations): flurazepam, Ro 15-1788, Ro 15-4513, midazolam, Ro 40-6129, and Ro 41-3380. In these experiments, flurazepam potentiation of I GABA was stabilized before measuring the rate of MTS modification as follows: 1) 1 M GABA and 1 M GABA ϩ 1 M flurazepam were applied to an oocyte; 2) the oocyte was treated with an EC 95 concentration of BZD and then washed for 3 min in ND96; and 3) flurazepam potentiation of I GABA was measured again using 1 M GABA and 1 M GABA ϩ 1 M flurazepam. This protocol was repeated until I GABA and I GABA ϩ flurazepam changed by less than 10% and demonstrated that the wash time was sufficient to wash out the test EC 95 concentration of BZD. In some cases, after treating the oocytes with MTS-reagent in the presence of a BZD, receptors were re-exposed to the same concentration of MTS-reagent alone to demonstrate that a maximal decrease in flurazepam potentiation of I GABA could still be obtained.
Homology Modeling of the BZD Binding Site. The mature protein sequences of the rat ␣ 1 and ␥ 2 subunits were modeled by comparison with the deduced three-dimensional structure of a subunit of the AChBP (Brejc et al., 2001 ). The crystal structure of the AChBP was downloaded from the Protein Data Bank (PDB code 1I9B) and loaded into Swiss Protein Databank Viewer (http://ca. expasy.org/spdbv). The mature ␣ 1 protein sequence from T12 to I222 and the mature ␥ 2 protein sequence from D26 to M233 were aligned with the AChBP primary amino acid sequence (Cromer et al., 2002) and threaded onto the AChBP tertiary structure using the "Interactive Magic Fit" function of Swiss Protein Databank Viewer. The threaded subunits were imported into SYBYL (Tripos, Inc., St. Louis, MO) and energy minimized (Ͻ 0.5 kcal/Å). The first 100 iterations were carried out using Simplex minimization (Press et al., 1988) followed by 1000 iterations using the Powell conjugate gradient method (Powell, 1977 ). An ␣ 1 /␥ 2 BZD binding site interface was assembled by overlaying the monomeric subunits on the AChBP scaffold and the resulting structure was imported into SYBYL and energy minimized. Docking of Ro 15-4513 was performed using AutoDock 3.0 (Morris et al., 1998) . The ligand started out in an arbitrary conformation, orientation, and position and the docking simulation was carried out using a Lamarckian genetic algorithm (Morris et al., 1998) . AutoDock 3.0, like other docking programs, treats the receptor protein as a fixed target; thus, in the final docked structure, the binding site residue side-chains have not moved.
Statistics. Data were analyzed by one-way analysis of variance, applying the Dunnett post-test for significance of differences between treatments (GraphPad). Comparisons used log(K I ) or log(k 2 ) values for the analysis.
Results
The Effect of Systematic ␥ 2 A79 Mutagenesis on i-BZD Binding Affinity. Ten point mutations were made at ␥ 2 A79 to evaluate the contribution of this residue to BZD ligand affinity (␥ 2 A793Gly, Ser, Cys, Glu, Gln, Leu, Phe, Tyr, Arg, Trp). These residues were chosen to represent a range of amino acid properties (i.e., size, charge, hydrophobicity). Wild-type ( (Table 1) . Only 3 of the 10 mutations at ␥ 2 A79 significantly altered flunitrazepam affinity. The ␥ 2 A79R, -C, and -Q mutations reduced flunitrazepam affinity 3-, 5-, and 9-fold, respectively. In contrast, 9 of the 10 mutations at ␥ 2 A79 significantly reduced the binding affinities of Ro 15-4513 and Ro 15-1788 (Table 1) . For Ro 15-4513, the decreases in affinity ranged from 6-(A79S) to 93-fold (A79F). For Ro 15-1788, the decreases ranged from 3-(A79S) to 21-fold (A79Y). Because mutations at ␥ 2 A79, in general, had larger affects on the binding affinities of i-BZDs than on flunitrazepam affinity, we hypothesized that ␥ 2 A79 lines a subsite of the BZD binding pocket important for i-BZD binding. Furthermore, the results implied that the chemical elements that are unique to i-BZDs (i.e., the imidazo ring and/or the 3Ј substituent) are probably near ␥ 2 A79.
To determine whether the 3Јsubstituent of i-BZDs was the Kucken et al. (2000) . n, number of independent experiments; N.D., data not determined. *, P Ͻ 0.05; **, P Ͻ 0.01; significantly different from wild-type receptors.
structural element responsible for the sensitivity of i-BZDs to ␥ 2 A79 mutation, midazolam binding affinity was examined.
Midazolam contains an imidazo ring that is similar to Ro 15-4513 and Ro 15-1788, but it does not possess a 3Ј substituent (see Fig. 1 ). The K I of midazolam was determined for several ␥ 2 A79 mutant receptors (␥ 2 A79G, -C, -E, -L, -R, and -Y). In general, the effects ␥ 2 A79 mutation had on midazolam affinity mirrored those observed for flunitrazepam rather than Ro 15-4513 or Ro 15-1788 (Table 1) (Fig. 2, Table 2 ). All three ligands bound to wild-type GABA A receptors with high affinity. All of the mutations significantly reduced, by 10-fold or more, the binding affinity of Ro 41-3380, which possesses the largest 3Ј imidazo substituent. Three of the five mutations significantly reduced the affinities of Ro 41-0639 and Ro 40-6129, which possess progressively smaller 3Ј substituents ( Table 2) .
The decreases observed in BZD binding affinity were examined as a function of 1) the 3Ј substituent volume and 2) the difference in accessible surface area between the side chain of the introduced residue and the wild-type alanine at position 79 (Fig. 3) . For all the mutant receptors tested, BZD binding affinity decreased with increasing bulkiness of the 3Ј substituent. In addition, as the surface area of the amino acid introduced at ␥ 2 A79 was increased, we observed correspondingly larger decreases in Ro 41-3380 binding affinity. Taken together, these data are consistent with a model in which ␥ 2 A79 lines a subsite within the BZD binding pocket that accommodates the 3Ј substituent of i-BZD ligands.
Ability of i-BZDs to Slow Sulfhydryl Modification of ␥ 2 A79C and ␥ 2 T81C. We compared the ability of flurazepam (positive modulator), midazolam (positive modulator), Ro 40-6129 (zero modulator), Ro 41-3380 (positive modulator), Ro 15-1788 (zero modulator) and Ro 15-4513 (negative modulator) to impede covalent modification of ␥ 2 A79C and ␥ 2 T81C. BZD ligands with different structures and functional efficacies were used to determine whether either of these properties influenced the ability of the ligand to slow the rate of covalent modification of cysteines substituted at ␥ 2 A79 and ␥ 2 T81. The rate of methanethiolsulfonate (MTS) modification of an engineered cysteine depends on several factors: 1) the permeability of the pathway to the substituted cysteine; 2) the electrostatic potential in the binding site and along the pathway; 3) the ionization of the sulfhydryl group; and 4) local steric restrictions. All of the ligands significantly slowed the rates at which MTSEA-Biotin and MTSEA-Biotin-CAP reacted with ␥ 2 A79C and ␥ 2 T81C, respectively (Fig. 4, Table 3 ).
Previously, we reported that sulfhydryl-modification of ␥ 2 A79C was slowed by the presence of both flurazepam and Ro 15-1788, whereas modification of ␥ 2 T81C seemed to be slowed only by Ro 15-1788 ( Teissére and Czajkowski, 2001) . Although the presence of flurazepam showed a clear trend in slowing the rate of MTSEA-Biotin-CAP modification of Table 2 .
␥ 2 T81C (29%), the rate was not statistically significant. Here, the inclusion of additional data demonstrated that flurazepam significantly slowed (39%) the rate of covalent modification of ␥ 2 T81C (Fig. 4, Table 3 ). Because differences in BZD functional efficacy did not alter the ability of the ligands to protect ␥ 2 A79C or ␥ 2 T81C from sulfhydryl modification, it is likely the protection is caused by a direct steric block of the substituted cysteines and not caused by allosteric conformational changes in the protein that accompany BZD binding. Differences in ligand structure also did not affect the ability of the ligands to protect either ␥ 2 A79C or ␥ 2 T81C from sulfhydryl modification. The results indicate that both classic BZDs and i-BZDs, when bound, lie topologically close to ␥ 2 A79 and ␥ 2 T81.
Discussion
The side-chains of ␥ 2 F77, ␥ 2 A79 and ␥ 2 T81 are located adjacent to each other on a ␤-strand within the BZD binding site (Teissére and Czajkowski, 2001 ). Mutagenesis of ␥ 2 F77 affects the binding affinity of both classic BZDs and i-BZDs (Buhr et al., 1997a; Sigel et al., 1998) , whereas mutagenesis of ␥ 2 A79 decreases the binding affinity of i-BZDs more than classic BZDs (Table 1) indicating that different residues within the binding pocket are important for stabilizing classic BZD and i-BZD binding. Both classic BZDs and i-BZDs, however, slow covalent modification of ␥ 2 A79 and ␥ 2 T81 (Fig.  4, Table 3 ). Thus, although classic BZDs do not require ␥ 2 A79 for high affinity binding, when bound they are located close enough to ␥ 2 A79C and ␥ 2 T81C to sterically interfere with the covalent addition of a sulfhydryl reagent at these positions.
Orientation of i-BZDs in the BZD Binding Site. Based on our experimental data, we propose that ␥ 2 A79 and ␥ 2 T81 line a region in which the 3Ј-imidazo substituent of i-BZDs is positioned. Several lines of evidence support this model of i-BZD orientation. Overall, ␥ 2 A79 mutations disrupt i-BZD binding to a greater extent than classic BZD binding which suggests that structural elements unique to i-BZDs (and not common elements, such Fig. 3 ). Furthermore, larger amino acid side chains introduced at ␥ 2 A79 cause correspondingly larger decreases in the binding affinities of iBZDs with bulky 3Ј substituents. These data can be explained by a model in which the addition of bulky side chains at position 79 decreases the volume of the binding site pocket and hinders occupation of the site by ligands bearing large 3Ј substituents, such as Ro 41-3380. A possible contradiction to this model is that the ␥ 2 A79R mutation did not disrupt the binding affinities of Ro 15-4513 or Ro 15-1788, which also possess fairly large 3Ј substituents (82.8 Å 3 ). However, a favorable interaction between the arginine side chain and the ester group of these compounds could overcome potential steric interference. It is also possible that the arginine side chain could interact with neighboring residues or with the Fig. 3 . The decreases observed in Ro 40-6129, Ro 41-0639, and Ro 41-3380 binding affinities after mutation of ␥ 2 A79 is correlated to the volume of the 3Ј-imidazo substituent. The log of the ratio K I -mutant/K I -wild-type is plotted as a function of 1) the volume (Å 3 ) of the 3Ј-imidazo substituent of Ro 40-6129 (45.4, OE), Ro 41-0639 (60.7, F), and Ro 41-3380 (109.6, f), and 2) the difference in accessible surface-area between the side chain of the introduced residue and the wild-type alanine. The accessible surface areas of the side chains were taken from Chothia (1976) and are listed in Table 2 . The K I values for mutant and wild-type receptors are reported in Table 2 . a Accessible surface areas for both alanine and threonine are reported, respectively. n, number of independent experiments. **, P Ͻ 0.01, significantly different from wild-type receptors.
Imidazobenzodiazepine Binding to the GABA A Receptor peptide backbone to minimize its impact on the binding of these ligands. Previously, we reported that conservative amino acid substitutions of ␥ 2 T81 resulted in small but significant decreases in i-BZD binding affinities (Kucken et al., 2000) . In this study, mutation of ␥ 2 T81 to cysteine significantly decreased the binding of the i-BZDs, Ro 40-6129, Ro 41-0639 and Ro 41-3380 between 3 and 8 fold ( Table 2 ). Mutation of ␥ 2 F77 to tyrosine has no affect on Ro 40-6129, Ro 41-0639 and Ro 41-3380 binding . Taken together, these data, in addition to the result that i-BZDs protect ␥ 2 A79C and ␥ 2 T81C from covalent modification, support the conclusion that ␥ 2 A79 and g 2 T81 line a region of the BZD binding pocket in which the 3Ј-imidazo substituent of i-BZDs is positioned.
Our data also suggest that there is a size limit to what can be accommodated within the binding cavity. Consistent with this idea, large substitutions at the 3Ј position of i-BZDs are not tolerated. For example, as the size of the ester group increases from CO 2 CH 2 CH 3 (Ro 15-1788) to CO 2 CH 2 C(CH 3 ) 3 , binding affinity is reduced 100-fold (Wong et al., 1993) . Mutations at ␥ 2 A79 affect Ro 15-4513 binding to a greater extent than Ro 15-1788 (Table 1) . One explanation of these results is that even though the 3Ј substituents of Ro 15- 4513 and Ro 15-1788 are the same size, the overall length of Ro 15-4513, from the 7-azide group to the end of the 3Јester substituent, is longer than Ro 15-1788 (Fig. 1) .
Interestingly, i-BZDs with small 3Ј substituents (e.g., CO 2 CH 3 ) also have decreased binding affinities (Wong et al., 1993) , suggesting that there may be an optimal size relationship between the 3Ј substituent and the binding site. Mutation of ␥ 2 A79 to a smaller residue (e.g., glycine) as well as to larger residues (e.g., phenylalanine, tyrosine) significantly decreases Ro 15-4513 and Ro 15-1788 binding affinities (Table 1) and suggests that size of the side chain at this position influences i-BZD binding affinity. Other amino acid properties, such as hydrophobicity, aromaticity, charge, and Hbonding capability, did not correlate with the decreases in i-BZD binding affinity measured after ␥ 2 A79 mutagenesis.
Homology Model of the BZD Binding Site. Much of our experimental data were completed before the publication of the molluscan AChBP crystal structure (Brejc et al., 2001) . To help facilitate discussion of our results and to provide additional support for our model of i-BZD orientation, we homology-modeled the benzodiazepine binding site using the to illustrate experimental protocol. B, current traces recorded from ␣ 1 ␤ 2 ␥ 2 T81C receptors after successive applications of MTSEA-Biotin-CAP ϩ FLZM. FLZM potentiation of GABA current was measured before and after each MTSEA-Biotin-CAP treatment. Note that after MTSEA-Biotin-CAP ϩ FLZM exposure, GABA-activated current increased in concert with a decrease in BZD potentiation as described previously in Teissére and Czajkowski (2001) . C, rate of sulfhydryl modification of ␣ 1 ␤ 2 ␥ 2 A79C (top) and ␣ 1 ␤ 2 ␥ 2 T81C (bottom) receptors in the absence and presence of . Observed decreases in the potentiation of I GABA by FLZM were plotted versus cumulative MTSEA-Biotin (A79C) or MTSEA-Biotin-CAP (T81C) exposure as described under Materials and Methods. Data from individual experiments were normalized to the flurazepam potentiation measured at t ϭ 0 and fit to single exponential decay curves (f, MTS alone; F, MTS ϩ 1 M midazolam; , MTS ϩ 1 M Ro 41-3380). Data points are mean Ϯ S.D. from at least three independent experiments. The calculated secondorder rate constants for the MTS reaction are presented in Table 3 . n, number of independent experiments. *, P Ͻ 0.05; **, P Ͻ 0.01; significantly different from control (MTS alone).
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structure of the AChBP as a template (Fig. 5) . It is important to recognize that the model is only a static picture of the BZD binding site captured in an indeterminate state. The homology model is based on the structure of the AChBP crystallized in the presence of the putative agonist HEPES. Because AChBP binds acetylcholine with high affinity, it has been hypothesized that this structure may represent receptor in either an open or desensitized state (Brejc et al., 2001) .
Prior data from our laboratory demonstrated that the region of the ␥ 2 subunit from T73 to T81 forms a ␤ strand (Teissére and Czajkowski, 2001 ). Our secondary structure prediction agrees with the crystal structure of the AChBP, where residues aligned with this region of the GABA A receptor form part of a ␤ strand (AChBP, ␤2). Many of the residues previously identified by mutagenesis, the substituted cysteine accessibility method (␣ 1 Y159, ␣ 1 T206, ␣ 1 Y209, ␥ 2 Y58, ␥ 2 F77, ␥ 2 A79, and ␥ 2 T81), and photoaffinity labeling (␣ 1 H101) as contributing to the BZD binding site Amin et al., 1997; Buhr et al., 1997a,b; Kucken et al., 2000; Teissére and Czajkowski, 2001) are positioned at the ␣ 1 /␥ 2 subunit interface and define a cavity that probably forms the BZD-binding site (Fig. 5A) .
In the absence of a crystal structure of the GABA A receptor bound with a BZD ligand, it is difficult to identify which residues directly contact a ligand and to predict how the ligands are oriented in the binding pocket. Ro 15-4513 can be used as a photoaffinity label for the BZD binding site of the GABA A receptor (Mohler et al., 1984; Sieghart et al., 1987) . The azide group at the 7 position of the fused diazepine ring (Fig. 1) is the photoreactive moiety and, when exposed to UV light, the aryl azide undergoes ring-expansion and subsequent bond formation with nearby nucleophilic groups (Hermanson, 1996) . Studies using both bovine brain and recombinant GABA A receptors have established that Ro 15-4513 photoincorporates into the ␣ subunit in a region that lies between G103 and the C terminus (Davies et al., 1996; . mapped a region of incorporation to the extracellular loop between transmembrane regions two and three. Recently, however, a site of Ro 15-4513 incorporation was mapped to a tyrosine residue equivalent to rat ␣ 1 Y209 (Sawyer et al., 2002) . Combining our data with this finding, we envision that Ro 15-4513 spans the binding site between ␣ 1 Y209 and ␥ 2 A79, with the azide substituent facing the ␣ 1 subunit and the 3Ј-imidazo substituent facing the ␥ 2 subunit. In agreement with our experimental data, computational docking of Ro 15-4513 into the BZD binding site positions the 3Ј-imidazo substituent of Ro 15-4513 near ␥ 2 A79 (Fig. 5, B and C) . The docking of Ro 15-1788 resulted in the same positioning of the 3Ј-imidazo substituent.
Although our data clearly define the orientation of i-BZDs within the binding site, how the binding of i-BZDs promote local movements within the binding site that are coupled to changes in GABA binding and/or GABA activation of the channel remains unknown. ) is a BZD agonist. According to allosteric theory, modulators that bind to a receptor protein exert their effects by initiating an allosteric transition in the protein that indirectly modifies the conformation of the agonist binding site (Changeux and Edelstein, 1998) . It is likely that functional coupling between the BZD and GABA binding sites is accompanied by structural rearrangements in the receptor protein that change the apparent affinity of both sites. Previously, we demonstrated that GABA binding and/or GABA-mediated receptor activation causes structural rearrangements in the BZD binding site that can be detected at A79 (Teissére and Czajkowski, 2001) . We speculate that BZD binding also promotes structural rearrangements within the BZD binding site and that these local changes determine how a particular BZD will modulate the GABA response. Because the therapeutic value of BZDs depends on their efficacy, identification of the residues mediating these local movements is an important goal for future studies.
